Johann de Bono

Professor Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research (ICR), an independent college of The University of London, and The Royal Marsden Hospital. He is the Head of the Division of Clinical Studies at the ICR and Director of The Royal Marsden Drug Development Unit. Professor De Bono is a world leader in prostate cancer research, having changed the treatment of prostate cancer multiple times through trials of abiraterone, cabazitaxel, enzalutamide and olaparib. He has also led on the clinical development of many other novel agents including the AKT inhibitor ipatasertib, multiple ATR inhibitors, multiple immunoconjugates and radioimmunoconjugates targeting for example tissue factor and PSMA, and multi-specific antibody constructs.